A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects - R256918OBE1008

Start Date13 Feb 2008

Sponsor / Collaborator-

NCT01041677 / CompletedPhase 2

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects

This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule). The primary objective of the study is to investigate mean changes in Hepatic Triglyceride Content (HTGC), which is the fat content of the liver, from baseline to week 6 and 12 by 1H-Magnetic Resonance Spectroscopy (MRS), a specialized non invasive radiology test. Additional measures include body mass index (BMI), fasting glucose,lipid levels, and blood pressure. Safety assessments performed during the trial include laboratory tests, vital sign measurements, and adverse event reporting.

Start Date01 Feb 2008

Sponsor / Collaborator

Johnson & Johnson Pharmaceutical Research & Development LLC

EUCTR2006-006772-38-GB / Not yet recruitingPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects - N/A

Start Date31 Dec 2007

Sponsor / Collaborator-

100 Clinical Results associated with Usistapide

100 Translational Medicine associated with Usistapide

100 Patents (Medical) associated with Usistapide

Literatures (Medical) associated with Usistapide

01 May 2010·IDrugs : the investigational drugs journal

American Society for Clinical Pharmacology and Therapeutics (ASCPT)-111th annual meeting. 17-20 March 2010, Atlanta, GA, USA.

Author: Veryard, Claire

The 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, held in Atlanta, included topics covering disclosures of new data in the field of pharmacokinetics and drug interactions. This conference report highlights selected presentations on pharmacokinetic studies of several investigational drugs, including evatanepag (Pfizer Inc), AEG-33773 (Aegera Therapeutics Inc), JNJ-16269110 (Johnson & Johnson Pharmaceutical Research & Development LLC), PF-3716539 (ViiV Healthcare), MK-0736 (Merck & Co Inc), a combination of Ginkgo biloba and cilostazol (Renexin SK Chemicals Co Ltd), PP-101 (Pacific Pharmaceuticals Co Ltd), ACT-178882 (Acetlion Ltd/Merck & Co Inc) and edoxaban (Daiichi Sankyo Co Ltd).

100 Deals associated with Usistapide

External Link

KEGG	Wiki	ATC	Drug Bank
D09986	-	-	DB12414

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	BE	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	DK	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	FI	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	DE	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	IN	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	NL	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	NO	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	PL	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	RU	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007
Diabetes Mellitus, Type 2	Phase 2	SE	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Dec 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis